Price$0.38-0.01 (-2.79%)
01:30 PM01:45 PM
News · 26 weeks32-73%
2025-12-142026-06-07
Mix2090d
- Other11(55%)
- SEC Filings9(45%)
Latest news
25 items- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRKaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholdersMIAMI, May 27, 2026 /CNW/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company"). This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.Unfortunately, BRTX shareholders are not currently gaining meaningful valu
- PRBioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataFully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILLE, N.Y., May 26, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the last patient has been dosed in its fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease (cLDD), completing treatment administration in the Company's lead clinical
- SECSEC Form 10-Q filed by BioRestorative Therapies Inc.10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsData demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland. The data highlight the functional and proteomic differences of extracellular vesicles ("EVs"), including exosomes, derive
- PRBioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseOral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety signals observed MELVILLE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, the Company's autologous hypoxic-cultured mesenchymal stem cell therapy for the treatment of chronic lumbar disc
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form 424B3 filed by BioRestorative Therapies Inc.424B3 - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical PlatformData demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it will present new data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, taking place May 6-9 in Dublin, Ireland. The Company will have two presentations at the conference: safety and blinded efficacy data from its fully enrolled, ongoing Phase 2 clinical trial in chronic lumbar disc disease, and preclinical data on its therapeutic an
- SECSEC Form EFFECT filed by BioRestorative Therapies Inc.EFFECT - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form POS AM filed by BioRestorative Therapies Inc.POS AM - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformCollaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic dermal, and consumer channels MELVILLE, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic partnership with David J. Goldberg, M.D., J.D., internationally recognized as one of the foremost innovators in laser dermatology, regenerative aesthetics, and clinical researc
- SECSEC Form POS AM filed by BioRestorative Therapies Inc.POS AM - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form DEF 14A filed by BioRestorative Therapies Inc.DEF 14A - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical PlatformPartnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic collaboration with 203 Creates, LLC, a Stamford, Connecticut-based firm specializing in the development, marketing, and growth of luxury, premium, and science-backed brands. The collaboration is designed to advance BioRestorative's biocosmeceutical platform by
- SECSEC Form PRE 14A filed by BioRestorative Therapies Inc.PRE 14A - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseData showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells Presented at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease, with 50% or more
- SECSEC Form 10-K filed by BioRestorative Therapies Inc.10-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseNew blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new blinded data on approximately 45 patients from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc dise
- PRBioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that members of its commercial leadership team will participate in the Be+Well Beauty and Wellness Show taking place March 8-10, 2026 at the Javits Center in New York City. The Be+Well trade show is one of the largest professional beauty, spa, and wellness trade events in the U.S., bringing together 35,000+
- PRBioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital StrategyCompany is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build momentum MELVILLE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today issued the following letter to shareholders from Chief Executive Officer Lance Alstodt: To our shareholders and stakeholders, The first quarter of 2026 marks a pivotal period for BioRestorative Therapies. We have achie
- PRBioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 DrugsGLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 202026566
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Announces Closing of $5.0 Million Public OfferingMELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.35 per share, are immediately exercisable and will expire five years from
BRTX FAQ
6 questionsWhat does BioRestorative Therapies Inc. do?
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical...Where does BRTX stock trade?
BioRestorative Therapies Inc. (BRTX) is listed on NASDAQ.What sector and industry is BRTX in?
BioRestorative Therapies Inc. operates in the Health Care sector, Managed Health Care industry.What are analysts saying about BRTX?
BioRestorative Therapies Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $3700.00 price target on 2021-12-01. Recent price targets cluster around $3700.00.What companies are similar to BRTX?
Notable peers in the same industry include CERN (Cerner Corporation), CHNG (Change Healthcare Inc.), AGTI (Agiliti Inc.), CO (Global Cord Blood Corporation), CSLT (Castlight Health Inc.). Compare BRTX side-by-side with any of them on Quantisnow.How can I track BRTX on Quantisnow?
Quantisnow aggregates BioRestorative Therapies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRTX to receive live email and push alerts on every new disclosure.